Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Patient must have histologically confirmed Stage I-IIIA non-small cell lung cancer (NSCLC) which is accessible to biopsy. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. * Life-expectancy greater than 6 months. * Adequate bone marrow, renal, hepatic, pulmonary and cardiac function as defined in the protocol. * Patient must be at least 18 years of age. * Must meet pre-entry requirements for timing of study parameters as specified in section 7.0. * Female patients of child-bearing potential must have a negative serum pregnancy test within 48 hours of study initiation and be non-lactating. * Patients of child-bearing potential must agree to use an effective form of contraception while on study and for 3 months following completion of study treatment. * The use of granulocyte-colony stimulating factor (G-CSF) will be permitted in study participants. * Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Exclusion Criteria: * Patient has received previous treatment for NSCLC. * Known hypersensitivity to everolimus, sirolimus, or any of its excipients. * Patient is pregnant or breast-feeding. * Patient has incurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patient is unable to swallow RAD001 tablet. * History of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of the malignancy being present within the past five years. * History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Symptoms may include any reaction such as bronchospasm, generalized urticaria, systolic BP ≤ 80mm Hg, and angioedema. * Final eligibility for a clinical trial is determined by the health professionals conducting the trial.